In July 1998, the Innovation Cardiotonic Pill (ICP) received approval for Investigational New Drug (IND) application from the U.S. FDA as a botanical drug. It is also recognized as an essential first-aid medicine in Traditional Chinese Medicine (TCM) hospitals across China.
Clinical studies show:
95.3% effectiveness for angina pectoris.
62.16% improvement in electro-cardiogram results.
ICP is widely used for its rapid action, high efficiency, low dosage, convenience, broad applications, and minimal side effects or toxicity.
Dilates coronary arteries and improves blood flow.
Increases cardiac output and reduces oxygen consumption.
Decreases blood platelet aggregation and prevents thrombosis.
Lowers blood and plasma viscosity.
Helps reduce cholesterol and blood lipid levels.
Improves cerebral blood flow and memory.
Protects against oxidative damage with little toxicity.
ICP is traditionally used for:
Coronary arteriosclerosis
Angina pectoris
Myocardial ischemia
Hyperlipidemia
Dizziness and memory decline caused by poor circulation
Radix Salvia Miltiorrhiza (Danshen) – 82.8%
Radix Notoginseng – 16.2%
Borneo Camphor Tree Gum – 1%
No irritation to the gastrointestinal tract.
No abnormal changes in heart, lung, liver, kidney, blood, urine, or stool after long-term use.
Broad safety range with little toxicity.
Caution: Not recommended for children under 12, pregnant or breastfeeding women.
General use: 1 capsule daily (oral or sublingual).
For acute angina: Take 10 pills (from inside capsule) sublingually every 10 minutes until pain subsides. Then continue with 1 capsule, 3 times daily for one month.
D.O.H Classification: Complementary Health Product.
Used by over 40 million people worldwide daily.
✅ Developed entirely by TASLY/KASLY Group
✅ Most popular choice in China for heart and circulatory health support